Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 6/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | GRK3 | P35626 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.44 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631026 | 0.89 | ABCB1 (0.52) | ABCB1ATMADRB2ADRB3CYP1A2 | |
| SCHEMBL5630529 | 0.88 | ADRB2 (0.51) | ADRB2ADRB3CYP1A2ADRB1LMNA | |
| SCHEMBL5632299 | 0.77 | L3MBTL1 (0.48) | ATMCYP1A2LMNACYP3A4ADRA1A | |
| SCHEMBL5632118 | 0.75 | PDE4A (0.46) | ABCB1ATMCYP1A2LMNACYP3A4 | |
| SCHEMBL5631023 | 0.75 | PTGS1 (0.53) | ADRB2ADRB3CYP1A2ADRB1LMNA | |
| SCHEMBL5632117 | 0.69 | PDE4A (0.48) | ABCB1ATMCYP1A2LMNACYP3A4 | |
| Tolamolol SCHEMBL613511 | 0.68 | ATM (0.59) | ABCB1ATMADRB2ADRB3CYP1A2 | |
| Tolamolol SCHEMBL611643 | 0.68 | ATM (0.59) | ABCB1ATMADRB2ADRB3CYP1A2 | |
| SCHEMBL5632239 | 0.68 | SRD5A2 (0.58) | ATMCYP1A2CYP3A4MAPK1SMN1; SMN2 | |
| Tolamolol SCHEMBL8057907 | 0.68 | ATM (0.58) | ABCB1ATMADRB2ADRB3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1565472-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ADRB3, PDE3A, PDE3B | ABCB1 947/4885ATM 3637/4885GRK3 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.